Library > eBooks

Home to the pharmaceutical heavyweights, Novartis and Roche, elite contract manufacturers and a dizzying array of acclaimed research institutions and medical institutes, Switzerland has long stood proud as a true powerhouse in medical discovery, drug development, and pharma…

Asia is at the forefront of new trends in precision medicine, from pioneering work in molecular diagnostics to increasingly tailored solutions in the war against cancer and in-depth genomic data sets better representing the profiles and needs of the region’s population.…

In our second edition of InFocus Five Biotechs to Watch in China, we profile five biotech companies that have all found their own differing routes to success. While it is always tricky to define the starting point of a revolution, the Chinese biopharma boom – whether one…

From how Asian countries can reclaim their ‘genetic destiny’ to an exploration of the ethnic differences in disease like cancer, diabetes and Hepatitis C, to some of the most exciting thematics including molecular diagnostics technology as well as cell and gene…

This inaugural edition of the InFocus Five Biotechs To Watch in China has selected companies at different stages of the biotech journey in order to showcase the diverse and multifaceted nature of Chinese biopharma innovation. While these companies are no doubt bound by a…

Produced in association with Novartis, InFocus Cell & Gene Therapy examines the remarkable progress of cell and gene therapies in recent years. Fast turning into a powerful engine of value creation for drug makers and representing a paradigm shift in the treatment of…

Long regarded as a neglected backwater within the drug discovery landscape and the preserve of only a handful of niche players, the rare disease space has been undergoing an extraordinary turnaround in fortunes of late. This special report delves into the flurry of…

While drug developers, healthcare practitioners and patients all rejoice at the advent of a golden age of scientific advancement in medicine – symbolized by recent radical breakthroughs in all manners of domains from stem cells and CAR-T generation immunotherapy to gene…

2017 was a comparatively quiet year for pharma M&A. However, conditions remain ripe for companies to engage in more deal making in 2018. Big Pharma is divesting its non-core assets and doubling down on core business lines. Furthermore, generics portfolios are…

As pharmaceutical and biotech products become more complex and the markets they serve more diverse, the healthcare logistics and distribution industry has had to consistently innovate and evolve to meet the needs of its clients. This report focuses on how this important…

This report offers companies, investors, policymakers, and stakeholders in-depth analysis of the benefits of blockchain technology in general and BioIPSeeds in particular, as well as expert insights into this game-changing technological breakthrough. The report…